|
1
|
Cockerell CJ: The pathology of melanoma.
Dermatol Clin. 30:445–468. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wisco OJ and Sober AJ: Prognostic factors
for melanoma. Dermatol Clin. 30:469–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tejera-Vaquerizo A, Solís-García E,
Ríos-Martín JJ and Moreno-Ramírez D: Primary cutaneous melanoma:
Prognostic factors not included in the classification of the
american joint committee on cancer. Actas Dermosifiliogr.
102:255–263. 2011.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katajisto P, Vallenius T, Vaahtomeri K,
Ekman N, Udd L, Tiainen M and Mäkelä TP: The LKB1 tumor suppressor
kinase in human disease. Biochim Biophys Acta. 1775:63–75.
2007.PubMed/NCBI
|
|
5
|
Hemminki A, Markie D, Tomlinson I,
Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M,
Höglund P, et al: A serine/threonine kinase gene defective in
Peutz-Jeghers syndrome. Nature. 391:184–187. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li J, Liu J, Li P, Mao X, Li W, Yang J and
Liu P: Loss of LKB1 disrupts breast epithelial cell polarity and
promotes breast cancer metastasis and invasion. J Exp Clin Cancer
Res. 33:702014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng B, Jeong JH, Asara JM, Yuan YY,
Granter SR, Chin L and Cantley LC: Oncogenic B-RAF negatively
regulates the tumor suppressor LKB1 to promote melanoma cell
proliferation. Mol Cell. 33:237–247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gan RY and Li HB: Recent progress on liver
kinase B1 (LKB1): Expression, regulation, downstream signaling and
cancer suppressive function. Int J Mol Sci. 15:16698–16718. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vaahtomeri K and Mäkelä TP: Molecular
mechanisms of tumor suppression by LKB1. FEBS Lett. 585:944–951.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Partanen JI, Tervonen TA, Myllynen M, Lind
E, Imai M, Katajisto P, Dijkgraaf GJ, Kovanen PE, Mäkelä TP, Werb Z
and Klefström J: Tumor suppressor function of Liver kinase B1
(Lkb1) is linked to regulation of epithelial integrity. Proc Natl
Acad Sci USA. 109:pp. E388–E397. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou W, Zhang J and Marcus AI: LKB1 tumor
suppressor: Therapeutic opportunities knock when LKB1 is
inactivated. Genes Dis. 1:64–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
de Wilde RF, Ottenhof NA, Jansen M,
Morsink FH, de Leng WW, Offerhaus GJ and Brosens LA: Analysis of
LKB1 mutations and other molecular alterations in pancreatic acinar
cell carcinoma. Mod Pathol. 24:1229–1236. 2012. View Article : Google Scholar
|
|
13
|
Lee SM, Choi JE, Na YK, Lee EJ, Lee WK,
Choi YY, Yoon GS, Jeon HS, Kim DS and Park JY: Genetic and
epigenetic alterations of the LKB1 gene and their associations with
mutations in TP53 and EGFR pathway genes in Korean non-small cell
lung cancers. Lung Cancer. 81:194–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guldberg P, Straten P thor, Ahrenkiel V,
Seremet T, Kirkin AF and Zeuthen J: Somatic mutation of the
Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma.
Oncogene. 18:1777–1780. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Abreu FB, Gallagher TL, Liu EZ and
Tsongalis GJ: Determining methylation status of methylguanine DNA
methyl transferase (MGMT) from formalin-fixed, paraffin embedded
tumor tissue. MethodsX. 1:42–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ekizoglu S, Dalay N, Karaman E, Akdeniz D,
Ozaydin A and Buyru N: LKB1 downregulation may be independent of
promoter methylation or FOXO3 expression in head and neck cancer.
Transl Res. 162:122–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He TY, Tsai LH, Huang CC, Chou MC and Lee
H: LKB1 loss at transcriptional level promotes tumor malignancy and
poor patient outcomes in colorectal cancer. Ann Surg Oncol. 21
Suppl 4:S703–S710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boland GM and Gershenwald JE: Principles
of melanoma staging. Cancer Treat Res. 167:131–148. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Retsas S, Henry K, Mohammed MQ and MacRae
K: Prognostic factors of cutaneous melanoma and a new staging
system proposed by the American Joint Committee on Cancer (AJCC):
Validation in a cohort of 1284 patients. Eur J Cancer. 38:511–516.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moreno-Ramírez D, Ojeda-Vila T,
Ríos-Martín JJ, Nieto-García A and Ferrándiz L: Association between
tumor size and Breslow's thickness in malignant melanoma: A
cross-sectional, multicenter study. Melanoma Res. 25:450–452. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gown AM, Goldstein LC, Barry TS, Kussick
SJ, Kandalaft PL, Kim PM and Tse CC: High concordance between
immunohistochemistry and fluorescence in situ hybridization testing
for HER2 status in breast cancer requires a normalized IHC scoring
system. Mod Pathol. 21:1271–1277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kokkat TJ, Patel MS, McGarvey D, LiVolsi
VA and Baloch ZW: Archived formalin-fixed paraffin-embedded (FFPE)
blocks: A valuable underexploited resource for extraction of DNA,
RNA, and protein. Biopreserv Biobank. 11:101–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan KT, Asokan SB, King SJ, Bo T, Dubose
ES, Liu W, Berginski ME, Simon JM, Davis IJ, Gomez SM, et al: LKB1
loss in melanoma disrupts directional migration toward
extracellular matrix cues. J Cell Biol. 207:299–315. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shin C and Tallon B: Assessment of tumor
mitotic rate in primary cutaneous malignant melanomas 1 mm or less
in thickness. J Am Acad Dermatol. 72:405–409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu W, Monahan KB, Pfefferle AD, Shimamura
T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE,
Castrillon DH, et al: LKB1/STK11 Inactivation leads to expansion of
a prometastatic tumor subpopulation in melanoma. Cancer Cell.
21:751–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Avizienyte E, Loukola A, Roth S, Hemminki
A, Tarkkanen M, Salovaara R, Arola J, Bützow R,
Husgafvel-Pursiainen K, Kokkola A, et al: LKB1 somatic mutations in
sporadic tumors. Am J Pathol. 154:677–681. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trojan J, Brieger A, Raedle J, Esteller M
and Zeuzem S: 5′-CpG island methylation of the LKB1/STK11 promoter
and allelic loss at chromosome 19p13.3 in sporadic colorectal
cancer. Gut. 47:272–276. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Esteller M, Avizienyte E, Corn PG, Lothe
RA, Baylin SB, Aaltonen LA and Herman JG: Epigenetic inactivation
of LKB1 in primary tumors associated with the Peutz-Jeghers
syndrome. Oncogene. 19:164–168. 2000. View Article : Google Scholar : PubMed/NCBI
|
